Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in the ICOS/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients.

Molecular immunology - 1 Apr 2018

Mao Yong, Wang Cheng, Meng Fanyi, Kong Jiehong, Cao Suping, Jiang Yiguo, Wang Weipeng, Hua Dong

Abstract excerpt

Polymorphisms within a gene's 3'-UTR may modulate posttranscriptional regulation of gene expression, and may explain individual sensitivity of chemotherapy. To investigate the correlation between single nucleotide polymorphisms (SNPs) in 3'-UTRs of B7/CD28 family genes and the response of capecitabine-based chemotherapy in colon cancer, 16 SNPs were identified in 274 advanced colon cancer patients. Statistical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Capecitabine

Share to Colonic Neoplasms

Share to History, 17th Century

Share to Inducible T-Cell Co-Stimulator Protein

Share to Oxaliplatin

Source

Identifiers

PMID: 29505962
DOI: 10.1016/j.molimm.2018.02.017

Genes

ICOS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in the ICOS/CD28-ICOSL pathway are related to capecitabine-based chemotherapy response in advanced colon cancer patients.PMID 29505962Read ↗

Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.Semantic proximity Read ↗

Five functional polymorphisms of B7/CD28 co-signaling molecules alter susceptibility to colorectal cancer.Semantic proximity Read ↗

The role of pharmacogenetics in capecitabine efficacy and toxicity.Semantic proximity Read ↗

Identification of new SNPs associated with severe toxicity to capecitabine.Semantic proximity Read ↗

Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.Semantic proximity Read ↗

Genetic variations in microRNA-binding sites of solute carrier transporter genes as predictors of clinical outcome in colorectal cancer.Semantic proximity Read ↗

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.Semantic proximity Read ↗

Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding.Semantic proximity Read ↗

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.Semantic proximity Read ↗

A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients.Semantic proximity Read ↗

A functional variant of IC53 correlates with the late onset of colorectal cancer.Semantic proximity Read ↗

Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.